Skip to content Skip to footer

Elucidating Genetic
Variation to Power
Genomic Medicine

Elucidating
Genetic Variation
to Power
Genomic Medicine

Our Mission

We are accelerating the development of life-saving precision diagnostics and therapeutics by elucidating the consequences of human genetic variation.

Our Edge

We specialize in integrating massively multiplexed functional genomics experiments with human biobank data using probabilistic machine learning.

Platforms

RareScan - Patient Expansion

More than half of people living with a rare disease remain undiagnosed and untreated.

Diagnoses are often complicated by variants of uncertain significance (VUS). Constantiam Biosciences’ RareScan™ platform uses Deep Mutational Scanning (DMS) to classify VUS and predict drug responses, improving patient access to treatments and improving clinical trial stratification for rare diseases.

Learn More

Genable - Target Discovery

Genable™ revolutionizes drug target discovery by using human genetic data, massively-multiplexed experiments, and machine learning to prioritize high-confidence targets.

This accelerates discovery, increases success rates, and reduces costs, offering a major advantage over traditional methods in developing precision diagnostics and therapies.

Learn More

StratiVar - Patient Stratification

StratiVar optimizes clinical trials enrollment by proactively assessing the susceptibility of all single amino acid variations of a targeted protein to a novel therapeutic.

These assessments are derived from drug-specific Deep Mutational Scans (DMS), centered on verified human data controls, and are translated into actionable insights including drug-sensitivity profile and predicted probabilities of patient response for clinical trial designers and physicians.

Learn More

MAVEvidence -
VUS
Resolution

MAVEvidence is the premier functional evidence resource for the clinical genetics community.

MAVEvidence delivers increased productivity and time savings through comprehensive curation, rigorous analysis, and clear presentation of functional evidence derived from high-throughput studies of genetic variants.

Learn More

RareScan – Patient Expansion

More than half of people living with a rare disease remain undiagnosed and untreated.

MAVEvidence® – VUS Resolution

MAVEvidence is the premier functional evidence resource for the clinical genetics community.

Genable – Target Discovery

Genable™ revolutionizes drug target discovery by using human genetic data, massively-multiplexed experiments, and machine learning to prioritize high-confidence targets.

This accelerates discovery, increases success rates, and reduces costs, offering a major advantage over traditional methods in developing precision diagnostics and therapies.

StratiVar – Patient Stratification

StratiVar optimizes clinical trials enrollment by proactively assessing the susceptibility of all single amino acid variations of a targeted protein to a novel therapeutic.

Functional Data for Clinical Decisions

Powered by deep mutational scanning and Bayesian generative modeling, MAVEvidence™ provides rigorous functional evidence for clinical genetics. It supports variant reclassification, improves diagnostic yield, and strengthens regulatory submissions.

Defining Patient Populations

Our massively multiplexed cellular assays classify thousands of variants of uncertain significance (VUS) with precision. RareScan™ identifies which variants are likely disease-causing and responsive to therapy helping pharma expand indications and accelerate trial enrollment.

Collaborative Impact

We partner with biopharma and diagnostics leaders to translate genomic uncertainty into actionable insight. Together, we enable earlier diagnoses, de-risk drug development, and bring life-changing therapies to rare disease patients faster.

Full Width Seamless Marquee

# Transforming Genomics # Transforming Genomics # Transforming Genomics # Transforming Genomics # Transforming Genomics # Transforming Genomics # Transforming Genomics # Transforming Genomics

Who We Are

Functional Genomics Powering Precision Medicine

About Us

Pioneering Innovation in Functional Genomics

At Constantiam Biosciences, we are redefining how genetic variants are interpreted. Too often, patients and drug developers face uncertainty when genetic test results yield variants of uncertain significance (VUS). We turn that uncertainty into evidence empowering better diagnoses, guiding therapeutic development, and accelerating precision medicine.

ML-powered functional evidence

Our platforms combine massively multiplexed assays with Bayesian generative modeling, producing functional evidence across thousands of variants in parallel.

Clinical and molecular insights

By linking variant effects to disease biology, we enable the reclassification of VUS, define patient populations, and predict treatment responsiveness.

Scalable, high-throughput platforms

RareScan® and MAVEvidence® deliver the scale and rigor needed to support pharma, diagnostics, and clinical genetics helping move rare disease care and drug development forward with confidence.